Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped up prior to trading on Thursday . The stock had previously closed at $39.79, but opened at $41.90. Zealand Pharma A/S shares last traded at $41.50, with a volume of 600 shares trading hands.

Analyst Ratings Changes

A number of research firms have weighed in on ZLDPF. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. BNP Paribas Exane lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

The stock has a market capitalization of $2.91 billion, a P/E ratio of 3.00 and a beta of 0.75. The stock has a 50 day simple moving average of $60.87 and a two-hundred day simple moving average of $69.86. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.53. The company had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $19.69 million. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%. On average, equities analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.